Molecular profiling by next-generation sequencing (NGS) of myeloid tumors has become a routine part of disease management. One of the difficulties and limitations of NGS technology has historically been the inability to reliably detect mutations in certain GC-rich gene regions (such as the CEBPA gene) and insertions/deletions in genes such as FLT3,?NPM1, and CALR.
Many labs have circumvented these limitations by performing parallel orthogonal testing, which is redundant, costly, and inefficient.?Furthermore, in late 2018, the US Food and Drug Administration approved a targeted therapy for?FLT3-mutated acute myeloid leukemia, making accurate and reproducible mutation detection of paramount importance for guiding treatment.
In this webinar,?Dr. Mohammad Hussaini of the Moffitt Cancer Center will?discuss development of a comprehensive?solution that captures 98 genes noted to be of importance in myeloid disease. In particular,?he will describe:??